A cohort study of vincristine-induced peripheral neuropathy in children

LI Chuang; JIN Jiao; HUANG Jing; YANG Xiao-Yan; LI Yan; YAN Yong-Yan; YANG Can

doi:10.7499/j.issn.1008-8830.2212032

PDF(565 KB)

Chinese Journal of Contemporary Pediatrics ›› 2023, Vol. 25 ›› Issue (5) : 470-475. DOI: 10.7499/j.issn.1008-8830.2212032

CLINICAL RESEARCH

A cohort study of vincristine-induced peripheral neuropathy in children

LI Chuang, JIN Jiao, HUANG Jing, YANG Xiao-Yan, LI Yan, YAN Yong-Yan, YANG Can

Author information +

History +

Abstract

Objective To study the characteristics of vincristine-induced peripheral neuropathy (VIPN) in children with acute lymphoblastic leukemia (ALL) and the factors influencing the development of VIPN. Methods The children with ALL, aged 1-18 years, who were treated with CCCG-ALL2015 or CCCG-ALL2020 regimen in the Affiliated Hospital of Guizhou Medical University from January 2018 to February 2022 were enrolled as subjects. According to the influence of age on risk, the children were divided into 1-10 years group with 91 children and >10 years group with 29 children. VIPN was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (5th edition), and the incidence rate, severity, and type of VIPN were compared between different groups. Results A total of 120 children were enrolled in this study, among whom 56 (46.7%) developed VIPN. The >10 years group had a significantly higher incidence rate of VIPN than the 1-10 years group (69% vs 40%, P<0.05). Among the 56 children with VIPN, 12 (21%) had grade 3 VIPN or above, and 44 (79%) had grade 2 VIPN. There were 77 cases of autonomic nerve symptoms (59.7%), 42 cases of peripheral nerve injury (32.5%), and 10 cases of cranial nerve injury (7.8%). There were no significant differences in the severity and type of VIPN between the groups with different ages, sexes, degrees of risk, or treatment regimens (P>0.05). The results of binary logistic regression analysis showed that age is the influencing factor for the occurrence of VIPN (P>0.05). Conclusions There is a relatively high incidence rate of VIPN in children with ALL, with the highest incidence rate of autonomic nervous symptoms. The incidence of VIP in children over 10 years old is relatively high.

Key words

Acute lymphoblastic leukemia / Vincristine / Peripheral neuropathy / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Chuang, JIN Jiao, HUANG Jing, YANG Xiao-Yan, LI Yan, YAN Yong-Yan, YANG Can. A cohort study of vincristine-induced peripheral neuropathy in children[J]. Chinese Journal of Contemporary Pediatrics. 2023, 25(5): 470-475 https://doi.org/10.7499/j.issn.1008-8830.2212032

References

1 赵贝贝, 陈晓娟, 郭晔, 等. 两种不同方案治疗儿童急性淋巴细胞白血病骨髓复发的临床观察[J]. 中国当代儿科杂志, 2020, 22(4): 346-349. PMID: 32312373. PMCID: PMC7389689. DOI: 10.7499/j.issn.1008-8830.1908035.
2 高伟, 蒋梦影, 高莉, 等. 儿童急性淋巴细胞白血病治疗失败的相关因素分析[J]. 中国实验血液学杂志, 2021, 29(3): 661-668. PMID: 34105454. DOI: 10.19746/j.cnki.issn1009-2137.2021.03.002.
3 van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer: a systematic review[J]. Crit Rev Oncol Hematol, 2017, 114: 114-130. PMID: 28477739. DOI: 10.1016/j.critrevonc.2017.04.004.
4 中国抗癌协会淋巴瘤专业委员会, 中国淋巴瘤南方协作组, 中国临床肿瘤学会抗淋巴瘤联盟. 长春碱类药物治疗恶性淋巴瘤中国专家共识[J]. 中国肿瘤临床, 2017, 44(5): 193-198. DOI: 10.3969/j.issn.1000-8179.2017.05.474.
5 任晓娟, 王玲, 张辉, 等. 长春新碱所致神经毒性机制的研究进展[J]. 中国小儿血液与肿瘤杂志, 2019, 24(4): 217-222. DOI: 10.3969/j.issn.1673-5323.2019.04.011.
6 Nazir HF, AlFutaisi A, Zacharia M, et al. Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: frequent autonomic and more severe cranial nerve involvement[J]. Pediatr Blood Cancer, 2017, 64(12): e26677. PMID: 28623857. DOI: 10.1002/pbc.26677.
7 Rosca L, Robert-Boire V, Delisle JF, et al. Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas[J]. Pediatr Blood Cancer, 2018, 65(11): e27351. PMID: 30014595. DOI: 10.1002/pbc.27351.
8 van de Velde ME, Kaspers GJL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in pediatric oncology: a randomized controlled trial comparing push injections with one-hour infusions (the VINCA trial)[J]. Cancers (Basel), 2020, 12(12): 3745. PMID: 33322788. PMCID: PMC7764775. DOI: 10.3390/cancers12123745.
9 Nikanjam M, Sun A, Albers M, et al. Vincristine-associated neuropathy with antifungal usage: a Kaiser Northern California experience[J]. J Pediatr Hematol Oncol, 2018, 40(5): e273-e277. PMID: 29771861. PMCID: PMC6019195. DOI: 10.1097/MPH.0000000000001220.
10 曾缘缘, 许静, 张永. 三唑类抗真菌药物与长春新碱联用致神经毒性的文献分析[J]. 中南药学, 2019, 17(6): 956-959. DOI: 10.7539/j.issn.1672-2981.2019.06.037.
11 Skiles JL, Chiang C, Li CH, et al. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer[J]. Pediatr Blood Cancer, 2018, 65(3): e26854. PMID: 29115708. PMCID: PMC5766375. DOI: 10.1002/pbc.26854.
12 Gilchrist LS, Tanner LR, Ness KK. Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer[J]. Pediatr Blood Cancer, 2017, 64(1): 180-187. PMID: 27567009. DOI: 10.1002/pbc.26204.
13 Lavoie Smith EM, Li L, Chiang C, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia[J]. J Peripher Nerv Syst, 2015, 20(1): 37-46. PMID: 25977177. PMCID: PMC4610712. DOI: 10.1111/jns.12114.
14 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007: 123-128.
15 Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. PMID: 27069254. DOI: 10.1182/blood-2016-03-643544.
16 Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia[J]. JAMA, 2015, 313(8): 815-823. PMID: 25710658. PMCID: PMC4377066. DOI: 10.1001/jama.2015.0894.
17 Kayilio?lu H, Kocak U, Kan Karaer D, et al. Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population[J]. J Pediatr Hematol Oncol, 2017, 39(6): 458-462. PMID: 28697165. DOI: 10.1097/MPH.0000000000000910.
18 姜嘉悦, 崔晓光. 长春新碱诱发周围神经病变治疗的研究进展[J]. 临床与病理杂志, 2021, 41(11): 2695-2700. DOI: 10.3978/j.issn.2095-6959.2021.11.032.
19 Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials[J]. J Clin Oncol, 2016, 34(25): 3014-3022. PMID: 27325863. PMCID: PMC5012713. DOI: 10.1200/JCO.2015.66.2346.
20 Wu W, Hill SE, Nathan WJ, et al. Neuronal enhancers are hotspots for DNA single-strand break repair[J]. Nature, 2021, 593(7859): 440-444. PMID: 33767446. PMCID: PMC9827709. DOI: 10.1038/s41586-021-03468-5.
21 Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population[J]. Pharmacogenet Genomics, 2016, 26(2): 100-102. PMID: 26618658. DOI: 10.1097/FPC.0000000000000191.
22 Yildiz FG, Temucin ?M. Vincristine-induced neurotoxicity: electrophysiological features in children[J]. Neurol Res, 2016, 38(2): 124-129. PMID: 27118608. DOI: 10.1080/01616412.2016.1139321.
23 Stadelmann C, Timmler S, Barrantes-Freer A, et al. Myelin in the central nervous system: structure, function, and pathology[J]. Physiol Rev, 2019, 99(3): 1381-1431. PMID: 31066630. DOI: 10.1152/physrev.00031.2018.
24 Old EA, Nadkarni S, Grist J, et al. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain[J]. J Clin Invest, 2014, 124(5): 2023-2036. PMID: 24743146. PMCID: PMC4001538. DOI: 10.1172/JCI71389.
25 Triarico S, Romano A, Attinà G, et al. Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment[J]. Int J Mol Sci, 2021, 22(8): 4112. PMID: 33923421. PMCID: PMC8073828. DOI: 10.3390/ijms22084112.